Want to see IN:KIMS full AI Analyst Report?
Top Page
Krishna Institute of Medical Sciences Limited
(KIMS)
Select Model
Select Model
Rating:56Neutral
Price Target:
₹876.00
▲(34.15% Upside)
Action:Reiterated
Date:05/17/26
The score is mainly constrained by weakening profitability, rising leverage, and deeply negative free cash flow despite strong revenue growth. Technicals are supportive with a clear uptrend, but valuation is a significant headwind due to the very high P/E.
Positive Factors
Strong multi-year revenue growth
Sustained 3x revenue expansion over 2021–2026 reflects durable demand for hospital services and successful network scale. Persistent top-line growth supports long-term investment payback, bargaining power with payers, and potential future operating leverage as fixed costs spread.
Negative Factors
Rising leverage and weaker balance sheet flexibility
A sharp rise in leverage materially increases financial risk and reduces optionality for growth or distress absorption. Higher debt ratios raise interest burden, constrain capital allocation, and elevate refinancing risk, limiting resilience to operational volatility over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong multi-year revenue growth
Sustained 3x revenue expansion over 2021–2026 reflects durable demand for hospital services and successful network scale. Persistent top-line growth supports long-term investment payback, bargaining power with payers, and potential future operating leverage as fixed costs spread.
Read all positive factors
Krishna Institute of Medical Sciences Limited (KIMS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹342.49B
Dividend YieldN/A
Average Volume (3M)23.04K
Price to Earnings (P/E)135.4
Beta (1Y)0.76
Revenue Growth28.65%
EPS Growth-37.22%
CountryIN
Employees5,013
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)8.39
Shares Outstanding420,006,470
10 Day Avg. Volume26,167
30 Day Avg. Volume23,042
Financial Highlights & Ratios
PEG Ratio-2.77
Price to Book (P/B)11.07
Price to Sales (P/S)6.37
P/FCF Ratio-22.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.02
Revenue Forecast (FY)₹51.23B
Krishna Institute of Medical Sciences Limited Business Overview & Revenue Model
Company Description
Krishna Institute of Medical Sciences Limited, known by its brand KIMS Hospitals across India, delivers a broad spectrum of medical and healthcare services. The institution boasts a comprehensive array of specialized fields, including cardiology, ...
How the Company Makes Money
KIMS primarily earns revenue by delivering hospital-based healthcare services across its facilities. Key revenue streams typically include: (1) Inpatient services: charges for admissions, room/bed occupancy, nursing care, intensive/critical care, ...
Krishna Institute of Medical Sciences Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
48
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.70B | 39.05B | 30.04B | 24.74B | 21.68B | 16.51B |
| Gross Profit | 20.12B | 21.31B | 18.77B | 15.21B | 13.41B | 10.34B |
| EBITDA | 8.24B | 8.20B | 8.24B | 6.52B | 6.43B | 5.46B |
| Net Income | 3.36B | 2.41B | 3.85B | 3.10B | 3.36B | 3.33B |
Balance Sheet | ||||||
| Total Assets | 66.25B | 77.59B | 57.36B | 38.52B | 29.41B | 19.07B |
| Cash, Cash Equivalents and Short-Term Investments | 1.74B | 898.00M | 1.02B | 1.32B | 1.34B | 1.90B |
| Total Debt | 31.87B | 42.53B | 25.57B | 13.55B | 6.78B | 2.57B |
| Total Liabilities | 40.49B | 52.00B | 33.17B | 17.59B | 10.03B | 4.97B |
| Stockholders Equity | 22.70B | 22.47B | 21.38B | 18.28B | 16.70B | 13.87B |
Cash Flow | ||||||
| Free Cash Flow | -4.69B | -11.15B | -4.27B | -1.26B | -1.42B | 1.54B |
| Operating Cash Flow | 2.85B | 3.13B | 5.82B | 5.21B | 4.32B | 3.24B |
| Investing Cash Flow | -7.17B | -15.69B | -11.16B | -7.53B | -5.47B | -4.12B |
| Financing Cash Flow | 4.57B | 12.55B | 5.43B | 2.17B | 196.42M | 609.99M |
Krishna Institute of Medical Sciences Limited Technical Analysis
Positive
653.00
Price Trends
770.29
Positive
722.63
Positive
697.38
Positive
Market Momentum
14.71
Positive
56.27
Neutral
33.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KIMS, the sentiment is Positive. The current price of 653 is below the 20-day moving average (MA) of 806.92, below the 50-day MA of 770.29, and below the 200-day MA of 697.38, indicating a bullish trend. The MACD of 14.71 indicates Positive momentum. The RSI at 56.27 is Neutral, neither overbought nor oversold. The STOCH value of 33.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KIMS.
Krishna Institute of Medical Sciences Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ₹1.27T | 65.46 | ― | 0.27% | 15.76% | 34.29% | |
67 Neutral | ₹730.84B | 70.14 | ― | 0.11% | 17.28% | 34.55% | |
66 Neutral | ₹359.38B | 64.55 | ― | 0.04% | 19.44% | 15.55% | |
64 Neutral | ₹414.18B | 51.16 | ― | 0.24% | 41.43% | 2.10% | |
61 Neutral | ₹1.08T | 74.72 | ― | 0.14% | 19.14% | 34.01% | |
56 Neutral | ₹342.49B | 135.37 | ― | ― | 28.65% | -37.22% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:KIMS
Krishna Institute of Medical Sciences Limited
815.45
106.60
15.04%
IN:APOLLOHOSP
Apollo Hospitals Enterprise Limited
8,841.55
1,645.18
22.86%
IN:FORTIS
Fortis Healthcare Ltd.
968.05
186.43
23.85%
IN:MAXHEALTH
Max Healthcare Institute Ltd
1,108.15
-139.88
-11.21%
IN:MEDANTA
Global Health Limited
1,336.65
10.33
0.78%
IN:NH
Narayana Hrudayalaya Ltd.
2,026.70
11.44
0.57%
Krishna Institute of Medical Sciences Limited Corporate Events
KIMS conducts compliant extraordinary general meeting via video conferencing
Jul 9, 2026
Krishna Institute of Medical Sciences Limited held an Extraordinary General Meeting (EGM) on July 9, 2026, conducted via video conferencing and other audio-visual means in line with MCA and SEBI circulars. The meeting was deemed to be held at the ...
KIMS issues corrigendum notice ahead of July 9 virtual EGM
Jul 5, 2026
Krishna Institute of Medical Sciences Limited has published newspaper advertisements in Financial Express and Navatelangana to inform shareholders about the dispatch of a corrigendum to the notice of its upcoming Extraordinary General Meeting. The...
KIMS Issues Corrigendum to EGM Notice on Preferential Share Issue
Jul 4, 2026
Krishna Institute of Medical Sciences Limited has issued a corrigendum to its previously circulated notice for an Extraordinary General Meeting scheduled on July 9, 2026, which will be conducted via video conferencing and other audio-visual means....
KIMS Issues Corrigendum to EGM Notice on Preferential Share Issue
Jul 4, 2026
Krishna Institute of Medical Sciences Limited has issued a corrigendum to its earlier notice convening an Extraordinary General Meeting on July 9, 2026, which will be held via video conferencing and other audio-visual means. The meeting includes a...
KIMS Raises ₹1,500 Crore via QIP, Boosts Equity Capital for Growth
Jun 19, 2026
Krishna Institute of Medical Sciences Limited has raised approximately ₹15,000 million through a qualified institutions placement, issuing 19,867,549 equity shares at ₹755 per share, representing a small discount to the floor price. Th...
KIMS Confirms SEBI-Compliant Dematerialisation of Shares for Q4 FY26
Apr 12, 2026
Krishna Institute of Medical Sciences Limited has submitted a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31 March 2026, as confirmed by its registrar and share ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.